Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $380.00.

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Oct. 15, 2024 — Experts have announced that the Sun has reached its solar maximum period, which could continue for the next year. Scientists will not be able to determine the exact peak of this ...